Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Madrigal Pharmaceuticals, Inc. filings document the company’s biopharmaceutical business, commercial reporting for Rezdiffra (resmetirom), and governance matters tied to its Nasdaq-listed common stock. Current reports include quarterly results furnished under Item 2.02, updates on Rezdiffra net sales and cash resources, and Regulation FD disclosures related to pipeline and licensing activity in MASH.
Other filings cover material agreements affecting Rezdiffra intellectual property and royalties, including amendments to a research, development and commercialization agreement, as well as proxy disclosures for director classes, board matters, executive compensation and equity incentive plans. The filing record also documents stockholder meeting proposals and corporate-governance actions for a commercial-stage biopharmaceutical company developing metabolic liver-disease therapies.
Madrigal Pharmaceuticals director Rebecca Taub reported an automatic sale of common stock tied to tax withholding. On the reported date, 491 shares of Madrigal Pharmaceuticals common stock were sold at an average price of $431.94 per share to cover tax obligations from vesting restricted stock units. After this transaction, Taub directly held 452,213 shares of common stock. She also reported indirect ownership of 655,540 shares held by SQN LLC, where she and her spouse are managing members, while disclaiming beneficial ownership of those shares beyond any pecuniary interest.
Madrigal Pharmaceuticals submitted Rule 144 notices reporting proposed and recent sales of Common Stock by insiders. The filing lists multiple historical sales, including 18,650 shares sold by Rebecca A. Taub on 01/09/2026 and 24,800 shares sold by Paul A. Friedman on 01/09/2026 The excerpt also shows a restricted stock unit vesting of 491 shares on 03/06/2026.
Madrigal Pharmaceuticals Chief Medical Officer David Soergel received new equity awards in the form of stock options and restricted stock units. On March 4, 2026, he was granted options for 5,467 shares at an exercise price of $0.00 per share and 4,374 shares of common stock as a restricted stock unit award.
The restricted stock units vest in four equal installments of 25% on March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, if he remains in service on each date. The option vests 25% on March 4, 2027, with an additional 6.25% vesting on the last day of each successive three‑month period, also subject to continued service. Following these grants, he directly holds 11,919 shares of common stock.
MDGL notice of proposed sale of 1,336 restricted stock units (RSUs) by an issuer-affiliated broker-dealer. The filing lists a trade date of 03/01/2026 and a prior sale of 1,183 common shares on 03/02/2026 reporting proceeds of $505,389.43.
Madrigal Pharmaceuticals EVP and CFO Mardi Dier had 1,183 shares of common stock sold at an average price of $427.21 per share. The shares were sold by the company on her behalf solely to cover tax withholding on vested restricted stock units, in an automatic, non-discretionary transaction. After this sale, she continues to hold 9,257 shares directly.
Madrigal Pharmaceuticals filed a Form 144 disclosing the proposed sale of 1,183 shares of Common Stock in connection with a Restricted Stock Unit grant that vested on 03/02/2026. The filing also reports a prior sale by a 10b5-1 plan of 4,173 shares on 12/02/2025 for $2,413,416.57.
Madrigal Pharmaceuticals director Richard S. Levy exercised stock options for 2,500 shares of common stock. The derivative transaction converted a fully vested stock option into 2,500 common shares at a price of $7.36 per share. Following this exercise, Levy directly owns 27,697 shares of Madrigal common stock.
Madrigal Pharmaceuticals is building a focused liver-disease franchise around Rezdiffra, its once-daily oral therapy for MASH with moderate to advanced fibrosis. Rezdiffra became the first approved treatment for this condition in the United States in March 2024 and received conditional marketing authorization in the European Union in August 2025, with launch in Germany that September.
For the year ended December 31, 2025, Madrigal generated $958.4 million in product revenue from Rezdiffra, with quarterly sales annualizing above $1.0 billion by year-end. The company is running long-term MAESTRO-NASH and MAESTRO-NASH OUTCOMES Phase 3 trials to convert accelerated approvals into full approvals and to expand into compensated cirrhosis, with key data expected in 2027 and 2028.
Madrigal is also using business development to build a combination-focused MASH pipeline. It entered a $500.0 million senior secured credit facility in July 2025, licensed oral GLP‑1 agonist MGL‑2086 from CSPC, Phase 2 DGAT‑2 inhibitor ervogastat from Pfizer, and six siRNA programs from Ribocure. As of February 12, 2026, the company had 22,939,969 common shares outstanding and a non‑affiliate equity value of about $5.6 billion as of June 30, 2025.
Madrigal Pharmaceuticals reported a breakout 2025, driven by its MASH drug Rezdiffra. Net revenues reached $321.1 million in the fourth quarter and $958.4 million for the full year, up sharply from $180.1 million a year earlier, with more than 36,250 patients on therapy by year-end.
Operating expenses also climbed, totaling $380.7 million in the quarter and $1,258.5 million for the year, reflecting heavy investment in commercialization and pipeline expansion. Madrigal ended 2025 with $988.6 million in cash and marketable securities and access to a senior secured credit facility of up to $500 million.
The company strengthened its long-term position with an Orange Book–listed Rezdiffra patent providing protection into 2045 and built an “industry-leading” MASH pipeline, including more than 10 programs such as siRNA candidates, an oral GLP-1 (MGL-2086), and the DGAT‑2 inhibitor ervogastat. Ongoing and planned trials aim to extend Rezdiffra’s use, including in compensated MASH cirrhosis (F4c).
Paulson & Co. Inc. filed an amended ownership report showing discretionary control over 1,707,522 shares of Madrigal Pharmaceuticals, Inc. common stock, representing 7.5% of the class. This percentage is based on 22,711,420 shares outstanding as of October 30, 2025.
The shares are owned by Paulson’s investment advisory clients, and Paulson disclaims beneficial ownership. Paulson reports sole voting and dispositive power over these shares and certifies the holdings are for investment purposes, not to change or influence control of Madrigal.